Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 18/20 | 0.47 |
| ▸ | JAK2 | O60674 | 5/20 | 0.44 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28173612 | 1.00 | PIK3C3 (0.48) | PIK3C3NTRK1JAK2NTRK3 | |
| SCHEMBL26968000 | 1.00 | PIK3C3 (0.48) | PIK3C3NTRK1JAK2NTRK3 | |
| SCHEMBL28918152 | 0.88 | NTRK1 (0.43) | PIK3C3NTRK1 | |
| SCHEMBL21097295 | 0.88 | NTRK1 (0.43) | PIK3C3NTRK1 | |
| SCHEMBL983254 | 0.81 | NTRK1 (0.48) | NTRK1JAK2 | |
| SCHEMBL988331 | 0.81 | NTRK1 (0.48) | NTRK1JAK2 | |
| SCHEMBL28173611 | 0.80 | PIK3C3 (0.46) | PIK3C3NTRK1JAK2NTRK3 | |
| SCHEMBL30279634 | 0.80 | PIK3C3 (0.46) | PIK3C3NTRK1JAK2 | |
| SCHEMBL28174455 | 0.80 | PIK3C3 (0.46) | PIK3C3NTRK1JAK2NTRK3 | |
| SCHEMBL3769485 | 0.80 | NTRK1 (0.49) | PIK3C3NTRK1JAK2NTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4294810-B1 | PROCESS FOR PREPARING HIGH PURITY DEGREE LAROTRECTINIB | OLON SPA (IT) | 2024-10-16 | — | — | EP | claimed |
| EP-4294810-B1 | PROCESS FOR PREPARING HIGH PURITY DEGREE LAROTRECTINIB | OLON SPA (IT) | 2024-10-16 | — | — | EP | disclosed |
| US-20240059696-A1 | PROCESS FOR PREPARING HIGH PURITY DEGREE LAROTRECTINIB | OLON S.P.A. (IT) | 2024-02-22 | — | — | US | disclosed |
| EP-4294810-A1 | PROCESS FOR PREPARING HIGH PURITY DEGREE LAROTRECTINIB | OLON S.p.A. (IT) | 2023-12-27 | — | — | EP | disclosed |
| EP-4294810-A1 | PROCESS FOR PREPARING HIGH PURITY DEGREE LAROTRECTINIB | OLON S.p.A. (IT) | 2023-12-27 | — | — | EP | disclosed |
| WO-2022175883-A1 | PROCESS FOR PREPARING HIGH PURITY DEGREE LAROTRECTINIB | OLON S.P.A. (IT) | 2022-08-25 | — | — | WO | disclosed |
| WO-2022175883-A1 | PROCESS FOR PREPARING HIGH PURITY DEGREE LAROTRECTINIB | OLON S.P.A. (IT) | 2022-08-25 | — | — | WO | disclosed |
| CN-110003214-B | Substituted pyrazolo [1,5-a ] pyrimidine compounds as TRK kinase inhibitors | 阵列生物制药公司 | 2021-12-21 | — | — | CN | disclosed |
| CN-109414442-A | (S) liquid preparation of-N- (5- ((R) -2- (2,5- difluorophenyl)-pyrrolidin-1-yl)-pyrazolo [1,5-A] pyrimidin-3-yl) -3- hydroxyl pyrrolidine -1- formamide | 洛克索肿瘤学股份有限公司 | 2019-03-01 | — | — | CN | disclosed |
| CN-109310694-A | METHODS OF TREATING PEDIATRIC CANCERS | 洛克索肿瘤学股份有限公司 | 2019-02-05 | — | — | CN | disclosed |
| CN-107428760-A | Crystalline forms of (S) -N- (5- ((R) -2- (2, 5-difluorophenyl) -pyrrolidin-1-yl) -pyrazolo [1,5-a ] pyrimidin-3-yl) -3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | 阵列生物制药公司 | 2017-12-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059696-A1 | PROCESS FOR PREPARING HIGH PURITY DEGREE LAROTRECTINIB | NTRK1, KDR, RPS27A | PIK3C3 1485/4885NTRK1 1/4885JAK2 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.